

CATHERINE A. SAZDANOFF



Board member and consultant with extensive experience in complex, highly-regulated industry: corporate development strategy and M&A, business development, global expansion and restructuring, legal, compliance and enterprise risk management.

PROFESSIONAL EXPERIENCE:

MERIDIAN BIOSCIENCE, INC. (NASDAQ: VIVO) 2015-present

Independent Director; Audit and Nominating/ Governance Committees

- Integrated diagnostics and life sciences company.

INMED PHARMACEUTICALS, INC. (TSX: IN; OTCQX: IMLFF) 2019-present

Independent Director; Chair, Nominating/ Governance and member, Audit and Compensation Committees

- Developing rare cannabinoid-based Rx treatments for high unmet-need diseases; proprietary bio-synthesis platform.

STRATA ONCOLOGY, INC. 2016-present

Strategy Advisor & Chief Compliance Officer (2019-present)

Business Advisor (2017-2019)

Chief Business Officer (2016-17)

- Private precision oncology company.
- Senior executive team; corporate strategy, business development, healthcare compliance, and legal/ IP strategy and management.

NEUROCERN, INC. 2016-present

Business Advisor

- Private neuro-informatics platform/ insurtech company.

SAZDANOFF CONSULTING LLC 2015 – present

President & CEO

- Healthcare business advisory services. Client examples: mProve Health (acquired 2017); women's health specialty pharma; Canadian generics company; drug repurposing pharma; startup with novel pain management therapy; stem cell R&D company.

UNIVERSITY OF CHICAGO 2018- present

- Lecturer, Business of Biotechnology professional certificate/ graduate credit program.
- Courses: Managing Operations and Board Relations; IP Law.

TAKEDA PHARMACEUTICALS 2006 - 2015

Global corporate roles (VP Global Business Development, 2011-13 & VP Head of Corporate Projects, 2012-15; VP Corporate Development, 2010-11; VP Global Licensing, 2008-10; Senior Director BD, 2006-08)

- Built and led corporate M&A team: strategy development, target evaluations, investment banker/ deal source management, all aspects of transactions.
- Lead negotiator and overall co-lead on acquisition of Nycomed S.A. for US\$ 13.7 billion in 2011 (>30% increase of Takeda revenue and EPS, direct presence in >60 countries), and of Millennium Pharmaceuticals for US\$ 8.8 billion in 2008 (oncology revenue, pipeline and capabilities).
- Led R&D BD team across all therapeutic areas (CNS, CV/ metabolic, immunology, respiratory, vaccines, GI and renal). BD strategy; multiple M&A and partnership evaluations and transactions; global integration; partnership governance.
- Led WW restructuring and enterprise risk management initiatives. Exceeded target for US\$ 500 million recurring savings.

ABBOTT LABORATORIES

1984 - 2006

Global corporate and pharmaceutical division roles (Office of Ethics & Compliance DVP and Senior Counsel; Senior Counsel, International Licensing & Acquisitions and global Litigation; Business Development/ Strategic Licensing Director; Senior Product Manager)

- Co-lead lawyer on US\$ 7 billion acquisition of Knoll Pharmaceuticals from BASF, adding multiple assets including mega-blockbuster Humira®.
- Lead lawyer and co-lead negotiator on multiple M&A and licensing deals, adding >US\$ 300 MM in revenue, pipeline products and technology rights.
- Increased market share for Biaxin® pediatric antibiotic by 50% in 6 months.
- Led pharmaceutical business development function; closed multiple licensing deals.
- Senior legal advisor for Europe and Canada.
- Roles of increasing responsibility for litigation worldwide (IP, antitrust, contracts, product liability, labor, regulatory, shareholder claims and mass tort litigation); 10-0 trial record.
- Legal advisor to pharmaceutical life cycle management team, extending exclusivity of selected products and adding US \$500 MM additional revenue.
- Successfully resolved infant formula antitrust matters, by trial (civil US \$9 billion claim; Puerto Rico government bid-rigging claim), settlement (FTC) and closure without charges (Canadian Competition Bureau). Favorably settled US federal fraud and abuse investigation in enteral nutrition business, including Corporate Integrity Agreement.
- Re-launched and globalized compliance program; designed and managed WW organization (~50 staff); directed strategic planning, risk assessments and internal investigations.

ISHAM, LINCOLN & BEALE, Chicago IL
Litigation associate.

1981 - 1983

EDUCATION:

J.D., Northwestern University School of Law
B.A. (English with honors), University of Notre Dame

PROFESSIONAL AFFILIATIONS: NACD; Women Corporate Directors; DirectWomen; Mentor-in-Residence at MATTER Chicago; Executive-in-Residence and External Advisory Board member for Rosalind Franklin University Innovation and Research Park; Cristo Rey St. Martin College Prep School Jobs Committee; Practicing Law Institute Advanced Licensing course faculty.